Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review
Narjes Sadat Farizani Gohari, Farahnaz Hoseinzadeh, Amirmohammad Khalaji, Samaneh Mirzaei, Mohsen Gholinataj jelodar · 2025
Read Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review by Narjes Sadat Farizani Gohari, Farahnaz Hoseinzadeh, Amirmohammad Khalaji, Samaneh Mirzaei, Mohsen Gholinataj jelodar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12707150.txt.
Description
Narjes Sadat Farizani Gohari and co-authors review scar-slowing drugs for lung disease tied to rheumatoid arthritis, in work from 2025. The joint disease can inflame and scar the lungs, worsening outlook sharply. Joint drugs control the joints well but help scarred lungs little.
Lung patterns in this setting mirror two known pneumonia-like forms. Genes, environment, and an overactive immune response feed slow fibroblast overgrowth. Drugs proven against a related lung scarring disease are now candidates here. The review weighs what evidence supports borrowing them. Trial gaps and safety questions in arthritis patients get attention. Matching drug choice to scar pattern is a recurring theme.
Catalog record
| CREATOR | Narjes Sadat Farizani Gohari, Farahnaz Hoseinzadeh, Amirmohammad Khalaji, Samaneh Mirzaei, Mohsen Gholinataj jelodar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |